237 related articles for article (PubMed ID: 20421814)
1. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
Liu F; Zhao B; Krug LM; Ishill NM; Lim RC; Guo P; Gorski M; Flores R; Moskowitz CS; Rusch VW; Schwartz LH
J Thorac Oncol; 2010 Jun; 5(6):879-84. PubMed ID: 20421814
[TBL] [Abstract][Full Text] [Related]
2. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
Pass HI; Temeck BK; Kranda K; Steinberg SM; Feuerstein IR
J Thorac Cardiovasc Surg; 1998 Feb; 115(2):310-7; discussion 317-8. PubMed ID: 9475525
[TBL] [Abstract][Full Text] [Related]
3. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
Creaney J; Francis RJ; Dick IM; Musk AW; Robinson BW; Byrne MJ; Nowak AK
Clin Cancer Res; 2011 Mar; 17(5):1181-9. PubMed ID: 21177406
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
Sugarbaker DJ; Gill RR; Yeap BY; Wolf AS; DaSilva MC; Baldini EH; Bueno R; Richards WG
J Thorac Cardiovasc Surg; 2013 Apr; 145(4):955-963. PubMed ID: 23434448
[TBL] [Abstract][Full Text] [Related]
6. A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
Rusch VW; Gill R; Mitchell A; Naidich D; Rice DC; Pass HI; Kindler HL; De Perrot M; Friedberg J;
Ann Thorac Surg; 2016 Oct; 102(4):1059-66. PubMed ID: 27596916
[TBL] [Abstract][Full Text] [Related]
7. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
[TBL] [Abstract][Full Text] [Related]
8. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.
Hasani A; Alvarez JM; Wyatt JM; Bydder S; Millward M; Byrne M; Musk AW; Nowak AK
J Thorac Oncol; 2009 Aug; 4(8):1010-6. PubMed ID: 19546819
[TBL] [Abstract][Full Text] [Related]
9. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
10. Miliary mesothelioma: a new clinical and radiological presentation in mesothelioma patients with prolonged survival after trimodality therapy.
Purek L; Laroumagne S; Dutau H; Maldonado F; Astoul P
J Thorac Oncol; 2011 Oct; 6(10):1753-6. PubMed ID: 21918389
[TBL] [Abstract][Full Text] [Related]
11. Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
Gill RR; Richards WG; Yeap BY; Matsuoka S; Wolf AS; Gerbaudo VH; Bueno R; Sugarbaker DJ; Hatabu H
AJR Am J Roentgenol; 2012 Feb; 198(2):359-63. PubMed ID: 22268178
[TBL] [Abstract][Full Text] [Related]
12. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F
Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622
[TBL] [Abstract][Full Text] [Related]
13. Malignant pleural mesothelioma: a population-based study of survival.
Milano MT; Zhang H
J Thorac Oncol; 2010 Nov; 5(11):1841-8. PubMed ID: 20975379
[TBL] [Abstract][Full Text] [Related]
14. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
Frauenfelder T; Tutic M; Weder W; Götti RP; Stahel RA; Seifert B; Opitz I
Eur Respir J; 2011 Jul; 38(1):162-8. PubMed ID: 21273389
[TBL] [Abstract][Full Text] [Related]
15. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
Werner-Wasik M; Xiao Y; Pequignot E; Curran WJ; Hauck W
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):56-61. PubMed ID: 11516851
[TBL] [Abstract][Full Text] [Related]
16. Trimodality treatment of malignant pleural mesothelioma.
Batirel HF; Metintas M; Caglar HB; Yildizeli B; Lacin T; Bostanci K; Akgul AG; Evman S; Yuksel M
J Thorac Oncol; 2008 May; 3(5):499-504. PubMed ID: 18449002
[TBL] [Abstract][Full Text] [Related]
17. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
Hollevoet K; Nackaerts K; Gosselin R; De Wever W; Bosquée L; De Vuyst P; Germonpré P; Kellen E; Legrand C; Kishi Y; Delanghe JR; van Meerbeeck JP
J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505
[TBL] [Abstract][Full Text] [Related]
18. Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
Labby ZE; Armato SG; Dignam JJ; Straus C; Kindler HL; Nowak AK
J Thorac Oncol; 2013 Apr; 8(4):478-86. PubMed ID: 23486268
[TBL] [Abstract][Full Text] [Related]
19. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma.
Lang-Lazdunski L; Bille A; Belcher E; Cane P; Landau D; Steele J; Taylor H; Spicer J
J Thorac Oncol; 2011 Oct; 6(10):1746-52. PubMed ID: 21876457
[TBL] [Abstract][Full Text] [Related]
20. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
Ribi K; Bernhard J; Schuller JC; Weder W; Bodis S; Jörger M; Betticher D; Schmid RA; Stupp R; Ris HB; Stahel RA;
Lung Cancer; 2008 Sep; 61(3):398-404. PubMed ID: 18433927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
